| Identification | Back Directory | [Name]
SIRT6-IN-1 | [CAS]
1214468-35-5 | [Synonyms]
1,2,3,4-Tetrahydro-2,4-dioxo-N-[4-(3-pyridinyloxy)phenyl]-6-quinazolinesulfonamide
2,4-dioxo-N-[4-(pyridin-3-yloxy)phenyl]-1,2,3,4-tetrahydroquinazoline-6-sulfonamide | [Molecular Formula]
C19H14N4O5S | [MDL Number]
MFCD11667663 | [MOL File]
1214468-35-5.mol | [Molecular Weight]
410.4 |
| Chemical Properties | Back Directory | [density ]
1.496±0.06 g/cm3(Predicted) | [storage temp. ]
-10 to -25°C | [solubility ]
DMSO (Slightly) | [form ]
Solid | [pka]
8.16±0.20(Predicted) | [color ]
Red to Very Dark Brown |
| Hazard Information | Back Directory | [Uses]
SIRT6-IN-1 is a novel SIRT6 inhibitor, with potential uses in treating in diabetes, immune-mediated disorders, and cancer. | [Biological Activity]
SIRT6-IN-1 (2,4-dioxo-N-(4-(pyridin-3-yloxy)phenyl)-1,2,3,4-tetrahydroquinazoline-6-sulfonamide) is a cell penetrantpotent and selective inhibitor of SIRT6 (Sirtuin 6). It improves glucose tolerance in a type 2 diabetes mouse model. SIRT6-IN-1 delays experimental autoimmune encephalomyelitis disease onset in mice. |
|
|